Blood-based biomarkers identify metastatic-castration-resistant-prostate-cancer patients who benefit from continuing enzalutamide beyond progression in combination with docetaxel in the PRESIDE trial

ID: 2513 Autores: Ruiz Vico, Maria (0); Ruiz-Vico, Maria (1,2,3); Wetterskog, Daniel (1); Orlando, Francesco (4); Thakali, Suparna (1); Wingate, Anna...